Evaxion Biotech A/S Files 2024 Annual Report
Ticker: EVAX · Form: 20-F · Filed: Apr 1, 2025 · CIK: 1828253
| Field | Detail |
|---|---|
| Company | Evaxion Biotech A/S (EVAX) |
| Form Type | 20-F |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, biotech, financials, personnel-changes
TL;DR
Evaxion Biotech's 2024 20-F is out, showing financials and exec changes. Check warrants and share prices.
AI Summary
Evaxion Biotech A/S filed its 20-F for the fiscal year ending December 31, 2024. The report details financial performance and business operations, including information on outstanding warrants and share prices. Key personnel changes noted include Mr. Norlén's resignation as CEO on September 1, 2023, and Mr. Vraniak's resignation as CFO.
Why It Matters
This filing provides investors with a comprehensive overview of Evaxion Biotech's financial health and strategic direction for the past fiscal year, impacting investment decisions.
Risk Assessment
Risk Level: medium — The company operates in the biotech sector, which is inherently high-risk due to research and development uncertainties and regulatory hurdles.
Key Numbers
- 20241231 — Fiscal Year End (The period covered by the 20-F filing.)
- 20250401 — Filing Date (The date the 20-F was submitted to the SEC.)
- 0001828253 — Central Index Key (Unique identifier for Evaxion Biotech A/S in SEC filings.)
Key Players & Entities
- Evaxion Biotech A/S (company) — Filer of the 20-F report
- Mr. Norlén (person) — Resigned as Chief Executive Officer effective September 1, 2023
- Mr. Vraniak (person) — Resigned as Chief Financial Officer
- USD 0.14 (dollar_amount) — Weighted average share price at exercise date for 2023
- USD 2.42 (dollar_amount) — Weighted average share price at exercise date for 2022
FAQ
What was the weighted average share price at the date of exercise for warrants in 2023?
The weighted average share price at the date of exercise for warrants in 2023 was USD 0.14.
When did Mr. Norlén resign as CEO?
Mr. Norlén resigned as the Chief Executive Officer of the Company effective September 1, 2023.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
What type of business is Evaxion Biotech A/S primarily involved in?
Evaxion Biotech A/S is primarily involved in Biological Products (No Diagnostic Substances).
What is the company's business address?
The company's business address is DR NEERGAARDS VEJ 5F, HOERSHOLM, G7, 2970.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 1, 2025 by Mr. Norlén regarding Evaxion Biotech A/S (EVAX).